Thursday, February 23, 2023 12:42:01 PM
Second highest volume day in company history. Not even finished yet. This could stair step for DAYS.
Company needs to release a nice PR.
Toss the shareholders a bone.
Float lock sends this to penny land quite fast , this is Wild West OTC :)
Company needs to release a nice PR.
Toss the shareholders a bone.
Float lock sends this to penny land quite fast , this is Wild West OTC :)
Recent PPCB News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/17/2026 09:30:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2026 08:01:28 PM
- Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd • GlobeNewswire Inc. • 07/07/2026 12:30:00 PM
- Propanc Biopharma Initiates $5.0 Million Share Repurchase Program • GlobeNewswire Inc. • 07/02/2026 12:30:00 PM
- Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study • GlobeNewswire Inc. • 06/16/2026 12:45:00 PM
- Clinical-Stage Biotech Rockets 308% After $5M Buyback and Phase 1 Cancer-Trial Path • AllPennyStocks.com • 06/11/2026 04:09:00 PM
- Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program • GlobeNewswire Inc. • 06/11/2026 12:30:00 PM
- Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain • GlobeNewswire Inc. • 06/02/2026 09:30:00 AM
- Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade • GlobeNewswire Inc. • 05/20/2026 12:45:00 PM
- Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients • GlobeNewswire Inc. • 05/19/2026 12:45:00 PM
- Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results • GlobeNewswire Inc. • 05/15/2026 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 09:30:07 PM
- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans • GlobeNewswire Inc. • 05/14/2026 02:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:18 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/10/2026 09:29:59 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 03/31/2026 10:12:48 AM
- Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain • GlobeNewswire Inc. • 03/24/2026 12:45:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/19/2026 09:30:42 PM
- Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy • GlobeNewswire Inc. • 03/12/2026 12:45:00 PM
- Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study • GlobeNewswire Inc. • 03/10/2026 12:45:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/06/2026 10:22:19 PM
- Propanc Biopharma Spotlights PRP as Potential Breakthrough for Metastatic Solid Tumors • IH Market News • 03/03/2026 03:34:06 PM
- Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models • GlobeNewswire Inc. • 03/03/2026 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:19:30 PM
